New treatment option for early breast cancer at high risk of recurrence

Matt Zeller, Novartis country president for Australia and New Zealand, said, “We welcome the PBS listing of KISQALI for node-positive patients at high risk of cancer recurrence. Importantly, this milestone provides the EBC community with more treatment choices, but we recognise there is still more work to be done." …